[Construction of autocatalytic caspase-3 and its effects of inducing apoptosis in human ovarian carcinoma].
Yue Song, Keng Shen
Abstract
Yue Song, Keng Shen
Abstract
OBJECTIVE: To construct the autocatalytic caspase-3 and investigate its apoptosis-inducing effect in ovarian cancer in vitro and in vivo. METHODS: PCR recombination technique was used to construct autocatalytic caspase-3 which is named as rev-caspase-3, and Ad-Max system was used to prepare recombinant adenovirus containing rev-caspase-3, which is named as Ad-rev-casp3. Immunohistochemistry was used to detect active caspase-3 expression. Cell counting kit, flow cytometry and western blot were used to measure cell survival rate, apoptotic rate, cell cycle distribution and the expressions of p17, active subunit of caspase-3, and p85, the poly (adenosine diphosphate-ribose) polymerase (PARP) cleavage segment, respectively. Transmission electron microscope was used to detect cell ultrastructure, and real time PCR was used to detect apoptosis-related gene expression. Subcutaneous tumor models and abdominally spread tumor models of human ovarian carcinoma were established using AO cells in BALB/c nude mice. The mouse survival rates were measured for abdominally spread tumor models, and the volume of tumor nodules were determined for subcutaneous tumor models following the treatments of rev-caspase-3. RESULTS: Active caspase-3 protein was significantly expressed, and the expression levels of active subunit of caspase-3, p17, and the PARP cleavage segment, p85, were significantly elevated in cells treated with rev-caspase-3. The decrease of cell survival rate and the increase of cell apoptotic rate were detected following Ad-rev-casp3 treatment. Treatments with Ad-rev-casp3 [multiplicity of infection (MOI) was 70] resulted in survival rate of 30.3% and apoptotic rate of 40.2%. There was a significant increase in cell number of S-phase (56.5%), while there was no significant apoptosis (3.4%) following treatments with Ad-rev-casp3 at a low dosage of MOI=10. Cells treated with rev-caspase-3 displayed significant apoptotic morphology. The levels of active caspase-3 gene expressions (9.44) significantly increased. Rev-caspase-3 treatment significantly prolonged survival, the mean survival duration was (213 +/- 16) days, and suppressed tumor growth (tumor growth suppression rate was 70%), when compared with treatment with phosphate buffered saline (PBS). CONCLUSION: Recombinant adenovirus containing rev-caspase-3 can significantly induce apoptosis of ovarian carcinoma cells, suppress tumor growth and prolong the mouse survival duration.
OpenAlex reports 2 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
OBJECTIVE: To construct the autocatalytic caspase-3 and investigate its apoptosis-inducing effect in ovarian cancer in vitro and in vivo. METHODS: PCR recombination technique was used to construct autocatalytic caspase-3 which is named as rev-caspase-3, and Ad-Max system was used to prepare recombinant adenovirus containing rev-caspase-3, which is named as Ad-rev-casp3. Immunohistochemistry was used to detect active caspase-3 expression. Cell counting kit, flow cytometry and western blot were used to measure cell survival rate, apoptotic rate, cell cycle distribution and the expressions of p17, active subunit of caspase-3, and p85, the poly (adenosine diphosphate-ribose) polymerase (PARP) cleavage segment, respectively. Transmission electron microscope was used to detect cell ultrastructure, and real time PCR was used to detect apoptosis-related gene expression. Subcutaneous tumor models and abdominally spread tumor models of human ovarian carcinoma were established using AO cells in BALB/c nude mice. The mouse survival rates were measured for abdominally spread tumor models, and the volume of tumor nodules were determined for subcutaneous tumor models following the treatments of rev-caspase-3. RESULTS: Active caspase-3 protein was significantly expressed, and the expression levels of active subunit of caspase-3, p17, and the PARP cleavage segment, p85, were significantly elevated in cells treated with rev-caspase-3. The decrease of cell survival rate and the increase of cell apoptotic rate were detected following Ad-rev-casp3 treatment. Treatments with Ad-rev-casp3 [multiplicity of infection (MOI) was 70] resulted in survival rate of 30.3% and apoptotic rate of 40.2%. There was a significant increase in cell number of S-phase (56.5%), while there was no significant apoptosis (3.4%) following treatments with Ad-rev-casp3 at a low dosage of MOI=10. Cells treated with rev-caspase-3 displayed significant apoptotic morphology. The levels of active caspase-3 gene expressions (9.44) significantly increased. Rev-caspase-3 treatment significantly prolonged survival, the mean survival duration was (213 +/- 16) days, and suppressed tumor growth (tumor growth suppression rate was 70%), when compared with treatment with phosphate buffered saline (PBS). CONCLUSION: Recombinant adenovirus containing rev-caspase-3 can significantly induce apoptosis of ovarian carcinoma cells, suppress tumor growth and prolong the mouse survival duration.
Key concepts: Apoptosis, Caspase 3, Flow cytometry, Molecular biology, Poly ADP ribose polymerase, Biology, Caspase, Ovarian cancer